Kelvin Chan, MD, FRCPC, MSc, PhD, on Opportunities to Optimize Cancer Drug Policies: The Canadian Perspective

First International Summit on Interventional Pharmacoeconomics

Leonard B. Saltz, MD, on Interventional Pharmacoeconomics: A Pathway to Better Cancer Care

Leonard B. Saltz, MD, of Memorial Sloan Kettering Cancer Center, discusses interventional pharmacoeconomics as an important tool that can offer patients with cancer more efficacious and cost-effective care. Pharmacoeconomics may help reduce the high costs of cancer therapy, with evidence-based reductions in doses that maintain effective treatment.

Boon-Cher Goh, MD, on Cancer Drugs in Singapore: 3As (Availability, Accessibility, and Affordability)

Mark J. Ratain, MD: The Justification for a Randomized Trial of Low-Dose Ibrutinib

Amit Sanyal, MD: A Clinician’s Perspective

Focus on Optimized Dosing of Ibrutinib Panel Discussion

Jun

Today In Oncology

Kelvin Chan, MD, FRCPC, MSc, PhD, on Opportunities to Optimize Cancer Drug Policies: The Canadian Perspective

Related Videos

Leonard B. Saltz, MD, on Interventional Pharmacoeconomics: A Pathway to Better Cancer Care

Boon-Cher Goh, MD, on Cancer Drugs in Singapore: 3As (Availability, Accessibility, and Affordability)

Mark J. Ratain, MD: The Justification for a Randomized Trial of Low-Dose Ibrutinib

Amit Sanyal, MD: A Clinician’s Perspective

Focus on Optimized Dosing of Ibrutinib Panel Discussion

FDA Approves Capivasertib Plus Abiraterone and Prednisone for Metastatic Prostate Cancer

AGA Recommends Colonoscopy Over Alternative Colorectal Cancer Screening Methods

AI-Assisted Tumor Volume Response Criteria Outperform Physician Assessments and RECIST Criteria in Pleural Mesothelioma

Overall Survival With EBRT in Hepatocellular Carcinoma

HCC TACE Plus STRIDE With or Without Lenvatinib